Brought to you by 
Arca, LabCorp develop diagnostic for prescribing bucindolol
06 Mar 2007
Executive Summary
Laboratory Corp. of America and ARCA Discovery will exclusively work together to create a genetic test to help physicians decide when to prescribe bucindolol, a Phase III next-generation beta blocker ARCA is developing for heart failure.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arca, LabCorp develop diagnostic for prescribing bucindolol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice